Pilot study II: Esketamine

Phase 1Small molecule

MMedical University of Vienna

Pilot study II: Esketamine is one of 8 small molecule programs targeting Ketamine. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KetamineRecruiting

KetaminePhase 1

Recruiting

Competition

Competitive Landscape

9 competitors in Ketamine

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

78 2

Ketalar

Boehringer Ingelheim

Phase 3

10 3

Spravato

WWim Janssens

Phase 2

2 4

Naltrexone Pill

YYale University

Phase 2

1 5

Fycompa

CCatalyst Biosciences

Phase 1

3 6

Ketamin

MMassachusetts General Hospital

Phase 1

1 7

Pilot study II: Esketamine

MMedical University of Vienna

Phase 1

1 8

Brevital Sodium

AAultman Health Foundation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ketamine1 trial

Imaging Neural Correlates of Ketamine Using PET/MR

Recruiting·MMedical University of Vienna·Phase 1·NCT04587778·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pilot study II: Esketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pilot study II: Esketamine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pilot study II: Esketamine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMedical University of Vienna

Pilot study II: Esketamine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ketamine1 trial

References

Drug Info

Quick Facts

Related News